Business
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior Advisor for Regulatory Affa
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"To enhance and accelerate regulatory dialogue with the FDA ","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"To provide strategic guidance across clinical development programs","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"To bring deep expertise in CNS and immuno-oncology","length":50,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":174,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior Advisor for Regulatory Affairs to support the advancement of its Phase III clinical program with vafidemstat in Borderline Personality Disorder (BPD).","length":447,"tagName":"p"},{"type":"text","content":"Dr. Barilero brings over 30 years of global regulatory leadership across CNS, neuropsychiatry, immuno-oncology, and rare diseases, with a proven track record in guiding Phase II–III programs, securing global approvals, and developing innovative regulatory pathways. Her expertise includes direct engagement with major health authorities including the FDA (CBER & CDER), EMA, PMDA, CFDA, Health Canada, ANVISA, and other.","length":424,"tagName":"p"},{"type":"text","content":"Her career spans academia, big pharma, and emerging biotechs, with a key highlight being her tenure as Vice President, Head of Global Regulatory Science for CNS at Lundbeck, where she led global regulatory strategies for breakthrough therapies targeting depression, bipolar disorder, schizophrenia, stroke, Alzheimer’s disease, Parkinson’s disease, and alcohol dependence. She played a pivotal ro...